In $57M Buyout, Invitrogen Adds Hepatocyte-Based Products Jan. 11, 2008 By Jennifer Boggs Research and discovery tools giant Invitrogen Corp. is expanding its portfolio yet again, with an agreement to acquire privately held CellzDirect Inc. for $57 million in cash. (BioWorld Today)Read More
RSS